Table 1 Basic features and quality assessments of the included studies.
Study, year | Study design | Origin country | TLRP/ELRP | Quality levels | |||
|---|---|---|---|---|---|---|---|
No. of Patients | Mean age (range) (years) | Mean PSA (ng/mL) | Mean Gleason score | ||||
Eden,2004 | CCT | England | 100/100 | 62.3(52–72)/61.4(45–73) | 7.7(2.0–27.0)/7.6(1.0–19.0) | 5.9(4.0–8.0)/6.1(4.0–9.0) | high |
Cathelineau,2004 | CCT | France | 100/100 | 63(49–76)/61 (48–75) | 8.9 ± 4.7/10.0 ± 8.0 | NA | high |
Ruiz,2004 | CCT | France | 165/165 | 64.1 ± 6.4/62.9 ± 6.8 | 10.8 ± 9.2/9.9 ± 8.7 | 5.7 ± 1.2/6.2 ± 1.0 | high |
Erdogru,2004 | CCT | Germany | 53/53 | 62.9 ± 5.4/62.9 ± 5.5 | 7.6 ± 3.8/7.4 ± 4.6 | 6.1 ± 0.8/6.0 ± 0.7 | high |
Remzi,2005 | CCT | Austria | 39/41 | 61.0 ± 11.0/59.0 ± 12.0 | 5.5 ± 3.7/8.1 ± 6.1 | 5.1 ± 1.2/5.5 ± 1.3 | high |
Brown,2005 | CCT | America | 122/34 | 58/56 | NA | NA | high |
Porpiglia,2006 | CCT | Italy | 80/80 | 64.2 ± 5.1/64.4 ± 5.9 | 8.3 ± 4.3/9.7 ± 5.7 | NA | high |
Katz,2006 | CCT | France | 22/13 | 67.5 ± 4.4/67.5 ± 4.4 | NA | NA | high |
Gao,2006 | CCT | China | 12/19 | 62.6 ± 6.7/63.1 ± 7.7 | 9.7 ± 3.1/8.8 ± 1.8 | NA | high |
Wang,2008 | CCT | China | 21/12 | 66(46–74)/66(56–73) | 28.9(9–120)/32.2(5–130) | 6.6(5.0–9.0)/7.0(6.0–9.0) | high |
Siqueira,2010 | CCT | Brazil | 40/40 | 59.8 ± 6.8/63.6 ± 7.9 | 5.4 ± 2.0/5.9 ± 1.9 | NA | high |
Wang,2010 | CCT | China | 39/15 | 68.1 ± 5.2/68.3 ± 6.1 | 15.4 ± 4.2/14.1 ± 6.3 | 7.4 ± 0.8/7.2 ± 0.7 | high |
San,2012 | CCT | China | 30/30 | 65.8(45–73)/66.1(42–70) | 36.2(5–130)/ 36.2(5–130) | 7.0(6.0–9.0)/7.0(6.0–9.0) | high |
Zhao,2014 | CCT | China | 116/74 | 66.8(50–78)/ 66.8(50–78) | 11.13(1.13–28.35)/11.13(1.13–28.35) | NA | high |
